Stock RGNX REGENXBIO INC.
Add to a list
To use this feature you must be a member
Log inSign up

News REGENXBIO Inc.

Equities

RGNX

US75901B1070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
18.02 USD -0.39% Intraday chart for REGENXBIO Inc. -6.10% +0.39%
Mar. 28 REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD CI
Mar. 18 Transcript : REGENXBIO Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 03:30 PM

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
REGENXBIO And Sarepta Agree To Stay Litigation Pending Outcome Of Sarepta's IPR Petition
AQ
One-time gene therapy could improve wet AMD
AQ
REGENXBIO Inc. Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
CI
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
PR
Transcript : REGENXBIO Inc. Presents at UBS Virtual CNS Day 2024, Mar-18-2024 03:30 PM
Transcript : REGENXBIO Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 through Mar-14-2024
HC Wainwright Initiates REGENXBIO With Buy Rating, $36 Price Target
MT
REGENXBIO to Participate in Upcoming Investor Conferences
PR
North American Morning Briefing : Stock Futures -2-
DJ
Regenxbio Insider Sold Shares Worth $365,220, According to a Recent SEC Filing
MT
RBC Upgrades REGENXBIO to Outperform From Sector Perform, Lifts Price Target to $35 From $20, 'Impressed by Recent Execution,' Keeps Speculative Risk
MT
REGENXBIO Announces Proposed Public Offering of Common Stock
AQ
North American Morning Briefing : Powell Still in -2-
DJ
Regenxbio Plans to Sell $125 Million in Equity Offering
MT
Leerink Partners Upgrades REGENXBIO to Outperform From Market Perform
MT
Baird Adjusts Price Target on REGENXBIO to $39 From $34, Maintains Outperform Rating
MT
REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE TRIAL
AQ
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
MT
Sector Update: Health Care
MT
Regenxbio Reports Higher Microdystrophin Expression in Phase 1/2 Duchenne Study
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RGNX Stock
  4. News REGENXBIO Inc.